GANX News and Press, Gain Therapeutics Inc. From 12/22/23

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

2023-12-19 17:03:57 ET More on Gain Therapeutics Gain Therapeutics prices stock and warrants offering to raise $9.4M Gain Therapeutics intends to offer its shares in a public offering Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earning...

BETHESDA, Md., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company’s Chief Execu...

Compounds significantly restored β-Gal function and reduced intracellular toxic substrates in model of GM1 gangliosidosis Results published in PLOS ONE in collaboration with Institute for Research in Biomedicine BETHESDA, Md., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Gain Therapeu...

BETHESDA, Md., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Matthias Alder, Chief Executive Officer, will ...

BETHESDA, Md., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the closing of an underwritten public offering of 2,545,000 shares of its common stock and warrants to purchase up to an aggregate of ...

2023-11-21 09:31:15 ET More on Gain Therapeutics Gain Therapeutics intends to offer its shares in a public offering Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeu...

BETHESDA, Md., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced the pricing of an underwritten public offering of 2,213,044 shares of its common stock and warrants to purchase up to an aggregate of ...

2023-11-20 17:34:17 ET Symbotic  ( SYM ) +20% . Veradigm  ( MDRX ) +6% . Tactile Systems Technology ( TCMD ) +6% . Farmer Brothers Company ( FARM ) +4% . Outset Medical ( OM ) +4% . MorphoSys  ( MOR ) -32% ...

2023-11-20 16:08:32 ET More on Gain Therapeutics Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeutics For further details see: Gain Therapeutics intends to offe...